XFOR: X4 Pharmaceuticals, Inc. Common Stock Company Profile & Statistics

X4 Pharmaceuticals, Inc. Common Stock Profile

About

X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States.

Info & Links

CEO

Paula Ragan

Headquarters

61 North Beacon Street, 4th Floor
Boston, MA 02134, UNITED STATES

Auditor

PricewaterhouseCoopers LLP

Share holders

Employees

143

X4 Pharmaceuticals, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

326.76M

Enterprise Value

363.38M

Enterprise Value/EBITDA(ttm)

-3.48

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

1.41

Price to Book(mrq)

8.10

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

76.38%

Operating Margin(ttm)

-311.15%

Profit Margin(ttm)

-2658.36%

Return on Equity(ttm)

-375.31%

Return on Invested Capital(ttm)

-99.99%

Return on Assets(ttm)

-72.87%

Income Statement

Revenue(ttm)

32.77M

Revenue Per Share(ttm)

2.87

Gross Profit(ttm)

27.20M

EBITDA(ttm)³

-104.52M

Net Income Available to Common(ttm)

-101.98M

Diluted EPS(ttm)

-14.84

Share Statistics

Beta (5Y Monthly)

0.51

52-Week Change

-73.75%

S&P 500 52-Week Change

19.94%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

11.41M

Dividend Yield

0.00%

Float⁴

11.16M

% Held by Insiders

2.15%

% Held by Institutions

72.03%

Balance Sheet

Total Cash(mrq)

62.95M

Total Cash Per Share(mrq)

5.52

Total Debt(mrq)

75.84M

Total Debt/Equity(mrq)

1909.87%

Current Ratio(mrq)

3.19%

Quick Ratio(mrq)

3.05%

Book Value Per Share(mrq)

0.50

Cash Flow

Operating Cash Flow Per Share(ytd)

-5.70

Free Cash Flow(ytd)

-42.27M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

XFOR

X4 Pharmaceuticals, Inc. Common Stock